NASDAQ:CDXC - ChromaDex Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.67
  • Forecasted Upside: 40.74 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.99 (-9.91%)
1 month | 3 months | 12 months
Get New ChromaDex Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CDXC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CDXC

Average Price Target: $12.67
▲ +40.74% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for ChromaDex in the last 3 months. The average price target is $12.67, with a high forecast of $18.00 and a low forecast of $9.00. The average price target represents a 40.74% upside from the last price of $9.00.


The current consensus among 3 investment analysts is to buy stock in ChromaDex. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2021HC WainwrightLower Price TargetBuy$16.00 ➝ $11.00High
5/10/2021HC WainwrightLower Price TargetBuy$11.00High
3/16/2021HC WainwrightBoost Price TargetBuy$7.00 ➝ $16.00High
3/10/2021OppenheimerInitiated CoverageBuy$9.00High
3/8/2021B. RileyBoost Price TargetBuy$7.00 ➝ $18.00High
12/2/2020OppenheimerReiterated RatingBuy$9.00High
11/5/2020OppenheimerReiterated RatingBuy$9.00High
10/12/2020HC WainwrightReiterated RatingBuy$7.00Low
10/6/2020OppenheimerBoost Price TargetOutperform$6.00 ➝ $9.00High
8/18/2020HC WainwrightReiterated RatingBuy$6.00 ➝ $7.00High
8/7/2020OppenheimerReiterated RatingBuy$6.00High
7/14/2020B. RileyReiterated RatingBuy$7.00Medium
5/13/2020OppenheimerInitiated CoverageBuy$6.00High
5/12/2020HC WainwrightReiterated RatingBuy$6.00High
4/21/2020OppenheimerReiterated RatingBuy$6.00Medium
3/9/2020B. RileyReiterated RatingBuyHigh
2/27/2020HC WainwrightReiterated RatingBuy$6.00Medium
1/21/2020HC WainwrightReiterated RatingBuy$6.00Low
10/15/2019OppenheimerInitiated CoverageOutperform$6.00High
5/28/2019HC WainwrightSet Price TargetBuy$7.00High
4/25/2019HC WainwrightReiterated RatingBuy$7.00High
3/8/2019B. RileyReiterated RatingBuyLow
2/14/2019B. RileyInitiated CoverageBuy$7.00 ➝ $7.00High
1/23/2019HC WainwrightSet Price TargetBuy$7.00Low
12/10/2018HC WainwrightSet Price TargetBuy$6.00High
9/19/2018HC WainwrightSet Price TargetBuy$8.00Low
9/10/2018HC WainwrightReiterated RatingBuy$8.00High
8/7/2018HC WainwrightReiterated RatingBuy$8.00High
7/16/2018HC WainwrightSet Price TargetBuy$8.00High
6/5/2018HC WainwrightSet Price TargetBuy$8.00Medium
5/14/2018HC WainwrightSet Price TargetBuy$8.00High
5/7/2018HC WainwrightSet Price TargetBuy$8.00Low
4/2/2018HC WainwrightSet Price TargetBuy$8.00High
3/11/2018HC WainwrightSet Price TargetBuy$8.00High
3/5/2018HC WainwrightSet Price TargetBuy$8.00Low
2/9/2018HC WainwrightSet Price TargetBuy$8.00High
1/23/2018HC WainwrightSet Price TargetBuy$8.00High
1/16/2018HC WainwrightSet Price TargetBuy$8.00High
12/15/2017HC WainwrightSet Price TargetBuy$8.00High
11/27/2017HC WainwrightBoost Price TargetBuy$6.00 ➝ $8.00Low
10/2/2017HC WainwrightReiterated RatingBuy$6.00N/A
9/25/2017LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$7.00N/A
9/11/2017HC WainwrightReiterated RatingBuyN/A
8/11/2017HC WainwrightSet Price TargetBuy$5.00N/A
3/20/2017HC WainwrightSet Price TargetBuy$6.00N/A
2/27/2017HC WainwrightSet Price TargetBuy$6.00N/A
2/16/2017HC WainwrightReiterated RatingBuy$6.00N/A
1/3/2017Rodman & RenshawInitiated CoverageBuy$6.00N/A
(Data available from 6/18/2016 forward)
ChromaDex logo
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety ecommerce platform, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
Read More

Today's Range

Now: $9.00
Low: $8.81
High: $10.02

50 Day Range

MA: $8.48
Low: $6.66
High: $10.54

52 Week Range

Now: $9.00
Low: $3.82
High: $23.66


1,178,517 shs

Average Volume

2,336,017 shs

Market Capitalization

$611.40 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of ChromaDex?

The following Wall Street sell-side analysts have issued reports on ChromaDex in the last twelve months: B. Riley, HC Wainwright, Oppenheimer Holdings Inc., and Zacks Investment Research.
View the latest analyst ratings for CDXC.

What is the current price target for ChromaDex?

3 Wall Street analysts have set twelve-month price targets for ChromaDex in the last year. Their average twelve-month price target is $12.67, suggesting a possible upside of 40.7%. B. Riley has the highest price target set, predicting CDXC will reach $18.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $9.00 for ChromaDex in the next year.
View the latest price targets for CDXC.

What is the current consensus analyst rating for ChromaDex?

ChromaDex currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CDXC will outperform the market and that investors should add to their positions of ChromaDex.
View the latest ratings for CDXC.

What other companies compete with ChromaDex?

How do I contact ChromaDex's investor relations team?

ChromaDex's physical mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The company's listed phone number is 310-388-6706 and its investor relations email address is [email protected] The official website for ChromaDex is